These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26980473)

  • 1. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.
    Huang J; Fan Q; Lu P; Ying J; Ma C; Liu W; Liu Y; Tan F; Sun Y
    J Thorac Oncol; 2016 Jun; 11(6):910-7. PubMed ID: 26980473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma.
    Wang X; Niu H; Fan Q; Lu P; Ma C; Liu W; Liu Y; Li W; Hu S; Ling Y; Guo L; Ying J; Huang J
    Oncotarget; 2016 Apr; 7(17):24744-51. PubMed ID: 27013591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial.
    Luo H; Jiang W; Ma L; Chen P; Fang M; Ding L; Hua Y; Du D; Jing Z; Xie R; Song Y; Wang J; Zhou R; Tian Z; Wu S
    JAMA Netw Open; 2020 Oct; 3(10):e2019440. PubMed ID: 33026449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.
    Xu J; Liu X; Yang S; Zhang X; Shi Y
    Asia Pac J Clin Oncol; 2017 Dec; 13(6):379-384. PubMed ID: 28276163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
    Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
    Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of icotinib in advanced lung squamous cell carcinoma.
    Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
    Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
    Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
    Wang HP; Zhang L; Wang YX; Tan FL; Xia Y; Ren GJ; Hu P; Jiang J; Wang MZ; Xiao Y
    Chin Med J (Engl); 2011 Jul; 124(13):1933. PubMed ID: 22088449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma.
    Wang H; Jiang D; Song Q; Xu C; Shi Y; Li X; Huang J; Xu Y; Sujie A; Zeng H; Zhong Y; Tan L; Hou Y
    Tumour Biol; 2016 Jul; 37(7):9771-9. PubMed ID: 26810066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
    Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
    Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
    Liu R; Liu L; Zhao C; Bai Y; Zheng Y; Zhang S; Li N; Yang J; Fan Q; Wang X; Zeng S; Zhang Y; Zhang W; Zhuang Y; Kang N; Jiang Y; Sun H; Xu J
    BMC Gastroenterol; 2021 Oct; 21(1):398. PubMed ID: 34688250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
    Liu J; Wu L; Wu G; Hu X; Zhou H; Chen J; Zhu M; Xu W; Tan F; Ding L; Wang Y; Shentu J
    Oncologist; 2016 Nov; 21(11):1294-1295d. PubMed ID: 27789778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of the telomerase RNA component gene as a new genetic marker for disease progression and prognosis in esophageal squamous cell carcinoma.
    Wang JD; Ma J; Wang FY; Peng LB; Wang X; Shi SS; Ma HH; Lu ZF; Lu GM; Zhou XJ
    Dis Esophagus; 2013; 26(7):737-45. PubMed ID: 23317107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.
    Hanawa M; Suzuki S; Dobashi Y; Yamane T; Kono K; Enomoto N; Ooi A
    Int J Cancer; 2006 Mar; 118(5):1173-80. PubMed ID: 16161046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
    Fan Y; Huang Z; Fang L; Miao L; Gong L; Yu H; Yang H; Lei T; Mao W
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):517-23. PubMed ID: 26148750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.